Express Scripts 2013 Annual Report Download - page 122

Download and view the complete annual report

Please find page 122 of the 2013 Express Scripts annual report below. You can navigate through the pages in the report by either clicking on the pages listed below, or by using the keyword search tool below to find specific information within the annual report.

Page out of 124

  • 1
  • 2
  • 3
  • 4
  • 5
  • 6
  • 7
  • 8
  • 9
  • 10
  • 11
  • 12
  • 13
  • 14
  • 15
  • 16
  • 17
  • 18
  • 19
  • 20
  • 21
  • 22
  • 23
  • 24
  • 25
  • 26
  • 27
  • 28
  • 29
  • 30
  • 31
  • 32
  • 33
  • 34
  • 35
  • 36
  • 37
  • 38
  • 39
  • 40
  • 41
  • 42
  • 43
  • 44
  • 45
  • 46
  • 47
  • 48
  • 49
  • 50
  • 51
  • 52
  • 53
  • 54
  • 55
  • 56
  • 57
  • 58
  • 59
  • 60
  • 61
  • 62
  • 63
  • 64
  • 65
  • 66
  • 67
  • 68
  • 69
  • 70
  • 71
  • 72
  • 73
  • 74
  • 75
  • 76
  • 77
  • 78
  • 79
  • 80
  • 81
  • 82
  • 83
  • 84
  • 85
  • 86
  • 87
  • 88
  • 89
  • 90
  • 91
  • 92
  • 93
  • 94
  • 95
  • 96
  • 97
  • 98
  • 99
  • 100
  • 101
  • 102
  • 103
  • 104
  • 105
  • 106
  • 107
  • 108
  • 109
  • 110
  • 111
  • 112
  • 113
  • 114
  • 115
  • 116
  • 117
  • 118
  • 119
  • 120
  • 121
  • 122
  • 123
  • 124

Express Scripts 2013 Annual Report 122
Keith Ebling
Executive Vice President &
General Counsel
Chris Houston
Senior Vice President
Operations
Ed Ignaczak
Executive Vice President
Sales & Marketing
Steve Miller, MD
Senior Vice President &
Chief Medical Offi cer
David Norton
Senior Vice President
Supply Chain
George Paz
Chairman & Chief Executive Offi cer
Cathy Smith
Executive Vice President &
Chief Financial Offi cer
Glen Stettin, MD
Senior Vice President
Clinical Research & New Solutions
Sara Wade
Senior Vice President &
Chief Human Resources Offi cer
Tim Wentworth
President & Chief Operating Offi cer
Gary Wimberly
Senior Vice President &
Chief Information Offi cer
Market Information
Our Common Stock is traded on the Nasdaq Global Select Market (“Nasdaq”) under the symbol ESRX. The high and low
prices, as reported by the Nasdaq, are set forth below for the periods indicated.
Fiscal Year 2013
Common Stock
High Low
First Quarter $60.08 $53.05
Second Quarter $64.08 $54.57
Third Quarter $67.66 $60.80
Fourth Quarter $70.79 $59.20
Fiscal Year 2012
Common Stock
High Low
First Quarter $55.34 $45.66
Second Quarter $58.98 $50.31
Third Quarter $64.46 $53.61
Fourth Quarter $66.06 $49.79
Comparative Stock Performance
The following graph shows changes over the past fi ve-year period in the value of $100 invested in:
(1) Our Common Stock; (2) S&P 500 Index; (3) S&P 500 Healthcare Index.
Total Return to Stockholders
(Dividends reinvested monthly) Base
Period Indexed Returns Years Ending
Company/Index Dec 08 Dec 09 Dec 10 Dec 11 Dec 12 Dec 13
Express Scripts 100 157.18 196.62 162.57 196.44 255.51
S&P 500 Index 100 123.45 139.23 139.23 157.90 204.63
S&P 500 - Healthcare 100 117.07 117.90 129.89 149.62 207.59
$0
$100
$200
$300
2008 2009 2010
Years Ending
2011 2012 2013
Express Scripts
S&P 500 Index
S&P 500
—
Healthcare
MANAGEMENT TEAM